Most Effective Treatment for Bipolar Disorder

A schizophrenia diagnosis arrives to a person in a small room, and rearranges things without asking — the way a conversation feels, the way a plan for next year suddenly needs rewriting, the way someone you love looks at you and you can't quite tell what they're thinking anymore. Most of what you'll read about schizophrenia treatment options is either clinical to the point of cold, or optimistic in a way that skips the hard parts. 

Schizophrenia is a chronic condition. In 2026, it is also named one of the most treatable severe mental illnesses in psychiatry. The medications have quietly changed over the last two years, with the care models changing even faster. And the question clinicians now ask (is this person living a life they recognize as their own?) is a better question than the one psychiatry asked a generation ago.

This is a guide to what schizophrenia treatment actually looks like now.

What "Treatment" Means for Schizophrenia in 2026

For most of psychiatry's history, treating schizophrenia meant turning down the volume on hallucinations and delusions and hoping everything else would hold. Consequently, it often didn't. The older medications were blunt instruments — they could quiet the psychosis while leaving a person sedated, emotionally flat, and unable to concentrate. A patient could be symptom-free on paper and still lose their apartment, their job, and their social world, not because the illness had won, but because the treatment had taken too much with it.

That old goal has been replaced.

The modern target is functional recovery: the ability to live a connected, productive life, be it work or school. Rebuilding the relationships that came apart during the acute phase. Living on your own terms. Functional recovery is not the same as symptom elimination. Some of the people who reach it still hear voices, and some of the people with zero symptoms can't hold a routine. What functional recovery actually requires, almost without exception, is a care plan that treats medication, therapy, physical health, and social support as one whole problem instead of four.

Pharmacological Breakthroughs: A New Era of Medication

Medication is the floor of schizophrenia treatment, not the ceiling. For about 40 years, that floor was built of one material: antipsychotics that bind dopamine D2 receptors and block the signal. That is still the starting point for most patients in 2026. What has quietly changed is the field, which now has options that were not there two years ago.

Second-Generation Antipsychotics: The Current Standard

Risperidone, olanzapine, aripiprazole, paliperidone, quetiapine. Those are the names that will likely appear first in any conversation with a psychiatrist. They're called "second-generation" or "atypical" antipsychotics because together, they work on dopamine and serotonin, producing a more favorable profile for negative symptoms and cognitive effects than the drugs that came before them.

They work. They also come at a cost.

The trade-off is metabolic. Weight gain. Elevated blood sugar. Shifts in lipid panels that, untracked, add up to real cardiovascular risk over time. A care team that prescribes these medications without monitoring the body is doing half the job. Metabolic monitoring is not optional.

The Non-Dopaminergic Revolution: Cobenfy and Muscarinic Agonists

In September 2024, something happened in schizophrenia pharmacology for the first time in about 35 years. The FDA approved xanomeline-trospium (Cobenfy, formerly known as KarXT), and the mechanism was not a variation on the dopamine theme. Cobenfy works on muscarinic receptors (specifically the M1 and M4 subtypes), meaning the biological pathway it acts on is different in kind, not just in detail (Yale Medicine).

Here is why that matters.

Roughly one-third of patients don't respond adequately to dopamine-based medications. The metabolic and movement-related side effects of the older drugs are also downstream of dopamine blockade. Cobenfy doesn't block dopamine, which is why early trials suggest it may avoid some of that side effect profile.

Long-term data is still accumulating. For now, the field has its first new mechanism in a generation.

Long-Acting Injectables: Reducing the Daily Burden

Long-acting injectable antipsychotics, or LAIs, deliver a single dose that lasts weeks or even months. For patients whose relapses have traced back to missed pills, that is a meaningful shift.

The evidence has caught up with the intuition. A 2022 network meta-analysis in World Psychiatry pooled 92 randomized trials and 22,645 participants and found that LAIs hold up against daily oral antipsychotics in preventing relapse (Ostuzzi et al., 2022). Real-world studies of US Medicare patients have shown LAIs are associated with lower rates of psychiatric hospitalization and treatment discontinuation.

LAIs are not right for every patient. Some people find meaning in the daily ritual of a pill. Some have had painful experiences with injections. The right answer comes out of a real conversation with a psychiatrist who has the patient's history in front of them.

Models of Care: Why the Environment Matters

The same medication can produce very different outcomes depending on how it is delivered. Two patients on the same dose of the same drug can end up in very different places a year later. The difference is usually the system around them.

Coordinated Specialty Care (CSC)

In 2026, coordinated Specialty Care is the standard for early psychosis.It is also one of the clearest examples in psychiatry of a care model producing better outcomes than a new drug would. The American Psychiatric Association formally endorsed it in its 2020 practice guideline (APA Practice Guideline for the Treatment of Patients With Schizophrenia), and it came out of the NIMH RAISE research initiative.

The model is a single team of clinicians working from one plan: medication management, individual therapy, supported employment and education, family education, and case management that actually happens, rather than getting sent to five different offices on five different days.

The data is strong. In the NIMH RAISE Early Treatment Program, patients who received CSC had hospitalization rates of 23% compared with 44% in usual community care (NIMH: Team-based Treatment is Better for First Episode Psychosis). They were also more likely to stay in school or employment and experienced greater improvement in symptoms, interpersonal relationships, and quality of life (Kane et al., American Journal of Psychiatry, 2016).

That is a halving of hospitalization risk, produced by a care model rather than a new molecule.

CSC was built for early psychosis. For patients further along in treatment, other models fit better.

Integrated Outpatient Care for Severe Mental Illness

For patients past the first-episode window, integrated outpatient care takes the same principle as CSC and adapts it for the long haul. The model brings psychiatrists, therapists, primary care physicians, dietitians, health coaches, peer mentors, and clinical care coordinators under one roof, working from a single shared plan.

The problem it solves is fragmentation. In the usual picture, a patient has a psychiatrist at one office, a therapist at another, a primary care provider at a third, and if case management exists at all, it runs on lost email attachments. Small things become crises. Crises become hospitalizations. Hospitalizations become the next relapse.

But it doesn't have to work that way.

This is the model our integrated outpatient clinics are built on. We see adults 18 and older. Our care team is designed so that mental health, physical health, and everyday function are handled in the same place, by people who talk to each other. The patient is not the one running the coordination.

Crisis Services and Long-Term Stability

Crisis services are not long-term care, and long-term care is not crisis services. Inpatient hospitalization exists to keep people safe when symptoms are acute. It is essential, and it saves lives. But it is not designed to produce long-term stability, and the handoff from inpatient to outpatient is the highest-risk period for readmission. That handoff is where integrated outpatient care earns its keep.

Evidence-Based Psychosocial Interventions

Medication does one job well. It quiets the biology. Everything else is outside what a pill can do: how a person thinks about what is happening to them, how they rebuild relationships that came apart during the acute phase, how they get back into work or school.

That is where psychosocial interventions come in.

Cognitive Behavioral Therapy for Psychosis (CBTp)

CBT for Psychosis, usually shortened to CBTp, is not standard CBT with a few tweaks. It is a specialized protocol built from the ground up for people who hear voices, hold persistent unusual beliefs, or are trying to function while symptoms are still present. The APA practice guideline gives CBTp a 1B rating, which translates roughly to "the evidence is strong and clinicians should offer this" (APA Practice Guideline, 2020).

What CBTp actually does in a session is teach specific skills. Reality testing. Cognitive distancing from distressing voices. Stress-reduction techniques for the moments when symptoms spike. Coping strategies for persistent delusions that have not responded fully to medication. The goal is not to eliminate the symptoms. It is to change the relationship a person has with them.

Social Skills and Vocational Training

Skills erode during acute episodes. A patient who was holding a job six months ago and had friends two years ago can come back from a hospitalization and find that the conversational rhythm, the workplace reflexes, and the social scaffolding are all gone. Not permanently. Just not where they left them.

Structured social skills training is what it sounds like: deliberate practice. Starting conversations. Reading a room at work. Managing conflict without escalation. Re-entering relationships that went quiet during the acute phase. Supported employment programs pair these skills with real job coaching, and the evidence is that they help people get and keep work when traditional vocational rehabilitation has not.

Cognitive Remediation

Hallucinations and mood can stabilize while the harder, quieter symptoms persist: forgetting appointments, losing the thread of a conversation, struggling to plan a week. These are the symptoms that sit between "stable" and "back to a life I recognize." For many patients, they are what actually prevents the return to work or school.

Cognitive remediation is structured training for those skills. Memory exercises. Attention work. Executive function practice. The programs are not new, but they are one of the most underprescribed interventions in this space. They will not cure cognitive symptoms, but they can meaningfully improve day-to-day function.

The Role of Family and Community Support

No one recovers from schizophrenia alone. That is not a sentimental claim, but a finding that has been reproduced in study after study over several decades.

Family psychoeducation is one of the most consistently supported non-medication interventions in the books. The idea is simple: when the people a patient lives with understand what schizophrenia is, what the medications do, and how to communicate in hard moments, relapse rates drop. A concept in the research called "expressed emotion" describes a household climate marked by high levels of criticism, hostility, or emotional over-involvement. When that climate softens, relapse rates soften with it. Nothing about this says families cause schizophrenia. They don't. But the environment in which treatment either catches or slips is incredibly important.

Community reintegration carries the same weight. A stable apartment. A part-time job, even a small one. Peer support groups. A faith community if that fits. Friendships that survive the acute phase. These are not "lifestyle" factors that sit outside treatment. They are the treatment. A patient with housing and a routine has a very different clinical trajectory from the same patient without them.

How to Choose Among Schizophrenia Treatment Options

The question families ask us is almost never "should we get treatment." It is "how do we pick the right place." A few things matter more than the rest in that decision.

Start with the intake. A good assessment is not a form that takes 20 minutes to fill out. It is a conversation that covers psychiatric history, medication history and response, current symptoms, physical health, substance use, the home situation, and what the patient actually wants out of treatment. If the intake is structured as a checklist, the treatment plan will be too.

Ask how the team communicates. Is there a dedicated case manager? Does the psychiatrist read the therapist's notes? Is metabolic monitoring built into the schedule? Is family involvement standard? Are outcomes tracked? These are the questions we built our care model to answer, and a clinic that stumbles on them is worth a second look.

Insist on shared decision-making. A patient is a participant in their treatment, not a recipient of it. A good clinician lays out the trade-offs of each medication in plain language, listens to what the patient wants, and makes decisions alongside them. A clinician who rushes that or waves it off is telling you something.

Frequently Asked Questions

Q: Can schizophrenia be cured?

Not cured in the traditional sense. Schizophrenia is managed, which is a word that sounds smaller than it is. "Managed" in 2026 can mean living for decades with minimal disruption, working, keeping relationships, and needing medical care the way a person with diabetes does. Functional recovery is achievable for a meaningful number of patients, though not all.

Q: What happens if I stop taking my medication?

The risk of relapse rises sharply. What makes stopping tricky is the delay. Many people who discontinue antipsychotic medication feel fine for weeks, sometimes months, before symptoms return. That gap is long enough to conclude the medication wasn't necessary, and then to be caught off guard when symptoms do come back. Talk to your prescriber before making any changes.

Q: Are there natural treatments for schizophrenia?

Sleep, exercise, nutrition, and stress management support mental health and matter for anyone living with schizophrenia. They are not a substitute for medical treatment. If something is marketed as a "natural cure" for schizophrenia, that is a reason to stop reading. Supplements, herbs, and alternative therapies have not been shown to treat the underlying biology of the condition. Some interact with prescribed medications in ways that can be dangerous.

Q: How do I help a loved one who refuses treatment?

This is the question we hear most from families, and it is the hardest one. A few things help:

• Anosognosia, a lack of awareness of one's illness, is itself a symptom of schizophrenia. It is not denial. Understanding the difference can change how you approach the conversation.
• The LEAP method (Listen, Empathize, Agree, Partner), developed by Dr. Xavier Amador, was built for exactly these situations.
• NAMI's Family-to-Family programs teach communication skills and connect families with others walking the same path.
• In an acute safety crisis, call 988, the Suicide and Crisis Lifeline, or your local mobile crisis team.

Moving Toward Functional Recovery

A schizophrenia diagnosis is a serious event. It is not a verdict.

The range of schizophrenia treatment options has meaningfully widened since 2024. New medications. New evidence about old medications. Care models with strong outcomes data. Psychosocial interventions that help with the parts of recovery medication cannot touch. The clinical goal has moved from quieting the biology to helping a person live a life they recognize as their own.

What most patients and families need is not a single treatment.

They need a team that treats the whole picture, which means symptoms, physical health, relationships, work, and function, as one problem instead of four.

If you or someone you love is living with schizophrenia, schizoaffective disorder, or a related condition, Amae Health is here to talk. Our care teams include psychiatrists, therapists, primary care providers, dietitians, health coaches, peer mentors, and clinical care coordinators, all working from one shared plan. We see adults 18 and older at our clinics in Los Angeles, Los Altos, San Mateo, Raleigh, New York, and Brooklyn. To start the conversation, request an intake appointment.

‍

Citations

1. 3 Things to Know About Cobenfy, Yale Medicine. Tier 4 (major academic medical center).
2. Ostuzzi et al., "Oral and long-acting antipsychotics for relapse prevention in schizophrenia-spectrum disorders: a network meta-analysis of 92 randomized trials including 22,645 participants," World Psychiatry, 2022. Tier 1 (peer-reviewed).
3. Kane et al., "Comprehensive Versus Usual Community Care for First-Episode Psychosis: 2-Year Outcomes From the NIMH RAISE Early Treatment Program," American Journal of Psychiatry, 2016. Tier 1 (peer-reviewed).
4. NIMH: Team-based Treatment is Better for First Episode Psychosis. Tier 2 (government).

The American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia, 2020. Tier 3 (professional association).

Days go by without a real conversation. Invitations stopped coming, or you stopped saying yes. At first it felt like rest. Now it feels like a wall. If you've been wondering what isolation is doing to you, or to someone you love, the research has a fairly clear answer: the negative effects of social isolation reach mood, the heart, sleep, and memory, and they build over time.

The good news is that connection works in both directions. The same research that shows the harm also suggests that rebuilding contact, even in small steps, matters.

What is social isolation?

The CDC defines social isolation as not having relationships, contact with, or support from others. It's something you can count: how often you talk to people, whether anyone would help in a crisis, whether you're part of any group.

Loneliness is different. It's the feeling of being alone or disconnected, the gap between the connection you have and the connection you want. You can be isolated without feeling lonely, and you can feel lonely in a room full of friends. The two often feed each other, and both carry health risks.

They're also common. According to the CDC, about 1 in 3 U.S. adults report feeling lonely, and about 1 in 4 report not having social and emotional support.

Who is most at risk?

The CDC lists several factors that raise the risk of isolation and loneliness, including:

• A chronic physical illness, disability, or a psychiatric or depressive condition
• Divorce, unemployment, or the loss of a loved one
• Living in a rural area, limited transportation, or language barriers
• Being a victim of violence or abuse
• Older age, living alone, low income, and being a young adult

Mental health conditions sit on both sides of the equation. Depression, anxiety, and psychosis can make people pull away, and isolation can make those conditions worse.

What does isolation do to a person mentally?

Depression

In a 2017 population-based study in PLOS ONE of 1,919 adults in Singapore, weak connections with relatives and friends, and loneliness, were both associated with more depressive symptoms, even after accounting for age, gender, employment, and other factors. Loneliness had the strongest association. The study was cross-sectional, so it shows a link rather than proving which came first, but the pattern matches what the CDC reports: isolation and loneliness raise the risk of depression and anxiety.

Suicidality and self-harm

The CDC also lists suicidality and self-harm among the health risks of isolation and loneliness. If you or someone you know is having thoughts of suicide, call or text 988, the Suicide & Crisis Lifeline. Reaching out is a form of connection too.

Withdrawal as an early warning sign

Sometimes isolation is a symptom rather than a cause. The NIMH lists withdrawing socially and spending much more time alone among the warning signs that can appear before a first episode of psychosis. Pulling away from people can also be a sign of depression, something we describe in what severe depression feels like. A sudden or growing withdrawal, especially in a teen or young adult, deserves attention. With psychosis, early care makes a difference. Read more about how we treat psychosis.

Effects of social isolation on the body

Heart disease and stroke

A 2022 scientific statement from the American Heart Association reviewed the research on isolation and cardiovascular health. It cited a meta-analysis in which social isolation or loneliness was linked to a 29% higher risk of coronary heart disease and a 32% higher risk of stroke. The authors also noted that the effect estimates are small and that unmeasured factors may play a role.

Stress hormones and inflammation

Isolation shows up in the body's stress systems. In a 2021 study in Psychoneuroendocrinology of 314 adults from the Midlife in the United States (MIDUS) study, living alone was associated with a flatter daily cortisol rhythm and higher C-reactive protein, a marker of inflammation. Loneliness was separately associated with higher levels of another inflammatory marker, IL-6.

A larger 2025 study in Nature Human Behaviour of 42,062 UK Biobank participants identified blood proteins linked to isolation and loneliness. Many were involved in inflammation and immune responses, and more than half were linked to later heart disease, type 2 diabetes, stroke, and death.

Earlier death

A 2015 meta-analysis in Perspectives on Psychological Science found that social isolation was associated with a 29% higher likelihood of death, loneliness with 26%, and living alone with 32%, after controlling for other factors. The authors concluded the risk is comparable to other well-established risk factors for mortality.

Effects on memory and the brain

In the English Longitudinal Study of Ageing, researchers followed 11,233 adults aged 50 and older over six assessments, two years apart. Isolation was associated with faster memory decline, particularly in men who were highly isolated at the start and in women whose isolation grew over time. The analysis suggested isolation contributed to memory decline, rather than poor memory causing isolation.

Dementia risk follows a similar pattern. In a nine-year U.S. study of 5,022 older adults published in the Journal of the American Geriatrics Society, being socially isolated was associated with a 28% higher risk of developing dementia, with no significant difference by race or ethnicity.

Signs that isolation is taking a toll

• Going days without a meaningful conversation
• Declining invitations or avoiding calls and messages
• Losing interest in activities you used to enjoy
• Sleep changes, low energy, or changes in appetite
• Persistent sadness, irritability, or feeling numb
• Neglecting self-care or your home
• Feeling like no one would notice if you disappeared

The last one is important. Feeling invisible or like a burden is a warning sign, and it's a reason to reach out today, or to call or text 988.

Can the effects of social isolation be reversed?

Much of the research is observational, so it shows risk rather than a guaranteed path back. But the ageing study found the strongest memory effects in people whose isolation was high or growing, which suggests the pattern over time matters. Reconnecting helps at any point, and the earlier the better.

Practical steps that help people rebuild contact include:

• Start small. One text, one short call, one coffee. Consistency matters more than size.
• Schedule it. Put regular check-ins with a friend or family member on the calendar.
• Join something structured. A class, volunteer role, faith community, or interest group gives you a reason to show up.
• Mix in-person and digital. Video calls help, but protect some in-person time too.
• Lower the bar. You don't need a deep conversation. Being around people counts.

If depression, anxiety, or another condition is what's keeping you isolated, treating it often makes reconnection possible in a way willpower alone doesn't.

When to get professional help

Talk to a mental health professional if isolation comes with persistent low mood, intense anxiety, loss of interest, neglect of basic self-care, or hopelessness that lasts for weeks. Get help sooner if someone is withdrawing alongside confused thinking, unusual beliefs, or hearing or seeing things others don't.

At Amae Health, our clinics specialize in conditions including Major Depressive Disorder, bipolar disorder, schizophrenia, and first-episode psychosis, where withdrawal is often part of the picture. Our care teams include psychiatrists, therapists, primary care physicians, care coordinators, and peer mentors who help with counseling and life skills. Group therapy is part of care too. For more on levels of care, see inpatient vs. outpatient mental health treatment. If reaching out feels hard, our guide on how to ask for help when depressed may help.

Frequently asked questions

What is the difference between social isolation and loneliness?

Social isolation is an objective lack of relationships, contact, or support. Loneliness is the subjective feeling of being alone or disconnected. You can have one without the other, and both are linked to health risks.

What does social isolation do to a person?

Research links isolation to more depressive symptoms, higher risk of heart disease and stroke, changes in stress hormones and inflammation, faster memory decline, higher dementia risk, and earlier death. Most of these findings are associations, and the risks build over time.

Why is isolation bad for your mental health?

Isolation removes support, routine, and the everyday contact that helps regulate mood. The CDC lists depression, anxiety, and suicidality among its health risks. Isolation can also be a symptom of depression or psychosis, which makes it a signal to notice.

How can I tell if someone is isolating because of a mental health condition?

Watch for withdrawal that's new or growing, combined with changes like low mood, poor self-care, confused thinking, or unusual beliefs. Ask directly and kindly how they're doing, and encourage an evaluation if the changes persist.

Key takeaways

• Social isolation is a lack of contact and support. Loneliness is the feeling of disconnection. Both carry health risks.
• Research links isolation to depression, heart disease and stroke, inflammation, memory decline, dementia, and earlier death.
• Withdrawal can also be an early sign of depression or psychosis.
• Small, regular steps toward connection help, and treating an underlying condition can make reconnecting possible.

If isolation is part of a bigger pattern of depression, mood swings, or changes in thinking, for you or someone you love, request an intake appointment. Our team will explain how an evaluation works and what the first visit involves.

TMS is not shock therapy. That is the first thing to settle in any TMS vs ECT comparison, because that phrase, and all the baggage that comes with it, refers to electroconvulsive therapy (ECT), not transcranial magnetic stimulation. TMS uses magnetic pulses, involves no anesthesia and no seizure, and you drive yourself home afterward. Both are evidence-based brain stimulation treatments for depression, and both work. They differ substantially in how they work, what the treatment is like to go through, and who they are typically used for. Knowing the difference between TMS and ECT is what lets you and your psychiatrist match the treatment to the situation.

What Is TMS?

Transcranial magnetic stimulation delivers focused magnetic pulses through a coil resting on the scalp to a specific region of the brain, usually the left dorsolateral prefrontal cortex, which is involved in mood regulation. The stimulation is targeted to that one site rather than generalized across the brain, and because it stimulates a small area without inducing a seizure, the procedure needs no anesthesia and takes place in an ordinary clinic or office, as the National Institute of Mental Health describes. FDA clearance came in 2008 for major depressive disorder, with obsessive-compulsive disorder added in 2018.

‍

At our clinics, a standard course of TMS therapy is 20 to 30 sessions, one per weekday, 30 to 40 minutes each, over about four to six weeks, and you sit awake in a chair for every one of them. No seizure is induced, nothing enters your bloodstream, and when the session ends you can drive yourself home and return to your day.

What Is ECT?

Electroconvulsive therapy is a controlled medical procedure performed under general anesthesia. You are given a short-acting anesthetic and an intravenous muscle relaxant to prevent movement, and electrodes on the scalp deliver a brief electrical current that produces seizure activity in the brain lasting under a minute. You wake within minutes, recover over the following hour or so, and need someone to take you home. A typical course is three sessions a week until symptoms improve, usually within 6 to 12 treatments.

‍

ECT is one of the oldest treatments in psychiatry and one of the most effective for severe depression. The FDA's clearance covers catatonia and severe depressive episodes in people age 13 and older with major depression or bipolar disorder who have not responded to other treatments or need a rapid response, and it is also used for mania and for certain presentations of schizophrenia and schizoaffective disorder. It is most often reserved for situations where fast, powerful relief matters: acute suicidality, depression with psychotic features, or catatonia.

‍

The stigma around ECT comes from portrayals that are decades out of date, from an era before anesthesia and muscle relaxants were used. Modern ECT is delivered in a monitored setting by a full medical team, and its main drawback is not what those old images suggest. It is the effect on memory, covered below.

TMS vs ECT: Side-by-Side Comparison

Effectiveness: What the Research Shows

Both treatments work. In head-to-head trials of electroconvulsive therapy vs TMS, ECT comes out ahead. A 2014 systematic review and meta-analysis in Depression Research and Treatment pooled nine randomized clinical trials comparing the two, with 384 participants in total. Both groups improved significantly. On the Hamilton Depression Rating Scale, the standard clinician-rated measure, scores fell by an average of 15.4 points with ECT and 9.3 points with TMS, a statistically significant difference (P = 0.011). The author concluded that ECT produced larger reductions in depressive symptoms, while the results also supported the therapeutic validity of TMS for people with treatment-resistant depression.

‍

A few things keep that finding in proportion. The trials were conducted between 2000 and 2011, largely with early TMS protocols. And "more effective" is not the same as "the right choice." Real-world TMS outcomes come from a different population. In naturalistic data from 42 U.S. clinics, 58% of outpatients with medication-resistant depression responded to a standard course and 37% reached remission. For someone whose depression has resisted medication but who is stable enough for outpatient care, that is the relevant number.

‍

In the head-to-head studies that exist, ECT delivers stronger short-term symptom reduction. TMS delivers a meaningful effect without anesthesia, without a hospital, and without the recovery and memory considerations described next.

Side Effects and Memory Concerns

Memory is the question people bring to this comparison more than any other, and it deserves a direct answer.

‍

ECT is associated with memory effects, particularly for events around the time of treatment. NIMH describes memory loss close to the treatment period that is sometimes more severe but usually improves over the days and weeks after the course ends, alongside headaches, upset stomach, muscle aches, and short-lived confusion. The largest analysis of the question, a 2010 meta-analysis in Biological Psychiatry covering 84 studies and 2,981 patients, found that measurable cognitive effects were mainly limited to the first three days after treatment. By 4 to 15 days, nearly all measures had recovered, and after 15 days processing speed, working memory, new learning, and some aspects of executive function had improved beyond where they were before treatment, most likely because the depression itself had lifted. Some people do report longer-lasting gaps in personal memories from the months around treatment, and that possibility belongs in the conversation before ECT.

‍

TMS carries no known negative effect on memory or thinking, and it requires no anesthesia. Its side effects are local: discomfort where the coil sits, tingling or twitching of scalp or facial muscles during the pulses, mild headache, and occasional brief lightheadedness. Those usually fade within the first week. Seizure is the one serious risk, and it is exceedingly rare. Screening for seizure history, metal in the head, and implanted devices is what keeps it that way.

What to Expect: The Treatment Experience

The daily reality of the two treatments could not be more different.

‍

A TMS session is a 30-to-40-minute appointment. You sit in a chair, awake, while the coil delivers pulses that feel like tapping on the scalp. When it ends, you stand up, get in your car, and go on with your day, then repeat tomorrow. There is no downtime and no preparation beyond an initial screening visit.

‍

An ECT session is a medical procedure. You fast beforehand, an IV is placed, and you are under anesthesia for a few minutes while the treatment is delivered in a hospital or specialized clinic with an anesthesia provider and a psychiatrist present. You wake up groggy, spend time in recovery, and need someone to take you home. Over several sessions a week for several weeks, that is a real commitment from you and whoever supports you, and ECT is sometimes delivered during an inpatient stay rather than as an outpatient.

Who Is Each Treatment Typically Recommended For?

These are different tools for different clinical pictures, not simply a better and a worse option.

‍

ECT is typically recommended when depression is severe, acute, or urgent, and the speed of response matters: someone at high risk of suicide, someone with psychotic depression, someone with catatonia, or someone who has not responded to multiple treatments. The trade-off of anesthesia and memory effects is accepted because the alternative is worse, and for anyone in that situation care for suicidal thoughts comes first.

‍

TMS is typically recommended for moderate or treatment-resistant depression in someone who is stable enough for outpatient care and can attend daily sessions, when there is no need for the fastest possible response. It is often the next step after antidepressants have failed and before ECT would be considered. For that person, a treatment without anesthesia, without memory effects, and without disruption to work or family life has real value, even if its average effect size is smaller.

Talking to a Psychiatrist About Your Options

Choosing between TMS and ECT is a clinical decision, made with a psychiatrist, that turns on three things: how severe your depression is, how urgently it needs to change, and what you have already tried. It is not a decision to make from a comparison table alone, including this one.

‍

At Amae, we offer TMS at our Los Angeles, Los Altos, and San Mateo clinics as part of our integrated outpatient clinics, where psychiatry, therapy, primary care, and peer support come from one team. We do not offer ECT. If our psychiatrists conclude that ECT is the better clinical fit for you, they will say so and help coordinate a referral, because the goal is the right treatment, not the treatment we happen to provide. If you are trying to work out where you stand, talk with an Amae psychiatrist. And if you are having thoughts of suicide right now, call or text 988, the Suicide and Crisis Lifeline.

Frequently Asked Questions

Is TMS the same as ECT?

No, and it is not "shock therapy" either. That phrase refers to ECT. TMS uses magnetic pulses targeted to one region of the brain, with no anesthesia and no seizure, and you stay awake and drive yourself home. ECT uses electrical stimulation to produce a brief, controlled seizure under general anesthesia in a monitored medical setting.

Does TMS cause memory loss like ECT can?

No. TMS has no known negative effect on memory or thinking; its side effects are scalp discomfort and headache, both short-lived and usually gone within a week. ECT can cause memory loss around the time of treatment that typically improves over the weeks after the course ends.

Which is more effective, TMS or ECT?

In head-to-head research, ECT produces larger short-term symptom reductions. A 2014 meta-analysis of nine randomized trials found average Hamilton scale drops of 15.4 points with ECT versus 9.3 with TMS, with both treatments producing significant improvement. TMS remains a well-supported outpatient option without anesthesia or recovery time, so "more effective" is not the same as "right for your situation."

Is ECT still used today?

Yes. ECT remains a well-established, evidence-based treatment, typically used for severe, urgent, psychotic, or catatonic depression and for depression that has not responded to other treatments. The stigma around it comes from decades-old portrayals that do not resemble modern practice.

Can you drive yourself home after TMS or ECT?

After TMS, yes. There is no anesthesia or sedation, so people typically drive themselves home and return to their day immediately. After ECT, no. General anesthesia means you need a support person to take you home and some recovery time before normal activities.

Does Amae Health offer ECT?

No. We offer TMS at our Los Angeles, Los Altos, and San Mateo clinics as part of integrated psychiatric care. We do not offer ECT, and if a psychiatrist concludes that ECT is the better fit for your situation, we help coordinate a referral to a provider who does.

‍

Citations

1. Micallef-Trigona B. Comparing the effects of repetitive transcranial magnetic stimulation and electroconvulsive therapy in the treatment of depression: a systematic review and meta-analysis. Depression Research and Treatment. 2014. https://pubmed.ncbi.nlm.nih.gov/25143831/
2. National Institute of Mental Health. Brain Stimulation Therapies. https://www.nimh.nih.gov/health/topics/brain-stimulation-therapies/brain-stimulation-therapies
3. Semkovska M, McLoughlin DM. Objective cognitive performance associated with electroconvulsive therapy for depression: a systematic review and meta-analysis. Biological Psychiatry. 2010. https://pubmed.ncbi.nlm.nih.gov/20673880/
4. Carpenter LL, Janicak PG, Aaronson ST, et al. Transcranial magnetic stimulation (TMS) for major depression: a multisite, naturalistic, observational study of acute treatment outcomes in clinical practice. Depression and Anxiety. 2012. https://pubmed.ncbi.nlm.nih.gov/22689344/
5. 988 Suicide and Crisis Lifeline. https://988lifeline.org

‍